SEC Comment Letter 0000000000-24-009811 to Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc.
Date: Aug. 28, 2024 · CIK: 0000926617 · Accession: 0000000000-24-009811
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281745
Letter
August 28, 2024 Nicole Sandford Chief Executive Officer & Director Aspira Women's Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 Re:Aspira Women's Health Inc. Registration Statement on Form S-3 Filed August 23, 2024 File No. 333-281745 Dear Nicole Sandford: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey J. Fessler, Esq.
Show Raw Text
August 28, 2024
Nicole Sandford
Chief Executive Officer & Director
Aspira Women's Health Inc.
12117 Bee Caves Road, Building III, Suite 100
Austin, TX 78738
Re:Aspira Women's Health Inc.
Registration Statement on Form S-3
Filed August 23, 2024
File No. 333-281745
Dear Nicole Sandford:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey J. Fessler, Esq.